$126.67
1.26% day before yesterday
Nasdaq, Nov 22, 10:00 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ

Jazz Pharmaceuticals Plc Target price 2024 - Analyst rating & recommendation

Jazz Pharmaceuticals Plc Classifications & Recommendation:

Buy
81%
Hold
19%

Jazz Pharmaceuticals Plc Price Target

Target Price $177.00
Price $126.67
Potential
Number of Estimates 18
18 Analysts have issued a price target Jazz Pharmaceuticals Plc 2025 . The average Jazz Pharmaceuticals Plc target price is $177.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 21 analysts: 17 Analysts recommend Jazz Pharmaceuticals Plc to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Jazz Pharmaceuticals Plc stock has an average upside potential 2025 of . Most analysts recommend the Jazz Pharmaceuticals Plc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Billion $ 3.83 4.04
4.78% 5.30%
EBITDA Margin 33.85% 45.74%
8.21% 35.11%
Net Margin 9.62% 12.55%
262.62% 30.52%

18 Analysts have issued a sales forecast Jazz Pharmaceuticals Plc 2024 . The average Jazz Pharmaceuticals Plc sales estimate is

$4.0b
Unlock
. This is
1.12% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$4.1b 1.77%
Unlock
, the lowest is
$4.0b 0.34%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $3.8b 4.78%
2024
$4.0b 5.30%
Unlock
2025
$4.3b 6.64%
Unlock
2026
$4.5b 4.08%
Unlock
2027
$4.8b 6.25%
Unlock
2028
$5.0b 5.70%
Unlock

7 Analysts have issued an Jazz Pharmaceuticals Plc EBITDA forecast 2024. The average Jazz Pharmaceuticals Plc EBITDA estimate is

$1.8b
Unlock
. This is
32.96% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$2.2b 61.49%
Unlock
, the lowest is
$1.7b 23.63%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $1.3b 3.83%
2024
$1.8b 42.27%
Unlock
2025
$1.8b 0.23%
Unlock
2026
$1.9b 3.83%
Unlock
2027
$2.3b 22.58%
Unlock
2028
$2.6b 9.87%
Unlock

EBITDA Margin

2023 33.85% 8.21%
2024
45.74% 35.11%
Unlock
2025
42.80% 6.43%
Unlock
2026
42.69% 0.26%
Unlock
2027
49.25% 15.37%
Unlock
2028
51.20% 3.96%
Unlock

8 Jazz Pharmaceuticals Plc Analysts have issued a net profit forecast 2024. The average Jazz Pharmaceuticals Plc net profit estimate is

$507m
Unlock
. This is
20.82% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$580m 38.33%
Unlock
, the lowest is
$432m 2.88%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $369m 270.39%
2024
$507m 37.46%
Unlock
2025
$647m 27.71%
Unlock
2026
$731m 12.99%
Unlock
2027
$1.1b 43.66%
Unlock
2028
$1.2b 9.79%
Unlock

Net Margin

2023 9.62% 262.62%
2024
12.55% 30.52%
Unlock
2025
15.03% 19.76%
Unlock
2026
16.32% 8.58%
Unlock
2027
22.07% 35.23%
Unlock
2028
22.92% 3.85%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 6.10 8.38
270.39% 37.38%
P/E 15.11
EV/Sales 2.78

8 Analysts have issued a Jazz Pharmaceuticals Plc forecast for earnings per share. The average Jazz Pharmaceuticals Plc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$8.38
Unlock
. This is
20.75% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$9.60 38.33%
Unlock
, the lowest is
$7.14 2.88%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $6.10 270.39%
2024
$8.38 37.38%
Unlock
2025
$10.71 27.80%
Unlock
2026
$12.10 12.98%
Unlock
2027
$17.38 43.64%
Unlock
2028
$19.09 9.84%
Unlock

P/E ratio

Current 18.24 90.88%
2024
15.11 17.16%
Unlock
2025
11.83 21.71%
Unlock
2026
10.47 11.50%
Unlock
2027
7.29 30.37%
Unlock
2028
6.64 8.92%
Unlock

Based on analysts' sales estimates for 2024, the Jazz Pharmaceuticals Plc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.82 9.32%
2024
2.78 1.26%
Unlock
2025
2.61 6.22%
Unlock
2026
2.51 3.92%
Unlock
2027
2.36 5.88%
Unlock
2028
2.23 5.40%
Unlock

P/S ratio

Current 1.92 4.12%
2024
1.90 1.11%
Unlock
2025
1.78 6.22%
Unlock
2026
1.71 3.92%
Unlock
2027
1.61 5.88%
Unlock
2028
1.52 5.40%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today